{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:44:36Z","timestamp":1775688276356,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/mnh.0b013e328365b3a3","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T15:43:28Z","timestamp":1381160608000},"page":"651-655","source":"Crossref","is-referenced-by-count":13,"title":["What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?"],"prefix":"10.1097","volume":"22","author":[{"given":"Sharon M.","family":"Moe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: a new paradigm.","volume":"14","author":"Moe","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"R2-10-20210205","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"R4-10-20210205","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.","volume":"26","author":"Moe","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R5-10-20210205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23klotho endocrine pathways.","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"key":"R6-10-20210205","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1006\/bbrc.2000.4226","article-title":"Severely reduced production of klotho in human chronic renal failure kidney.","volume":"280","author":"Koh","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"R7-10-20210205","first-page":"S1","article-title":"Kidney I","volume":"76","year":"2009","journal-title":"nt"},{"key":"R8-10-20210205","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.","volume":"2","author":"Chertow","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-10-20210205","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/ndt\/gfr777","article-title":"Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.","volume":"27","author":"Chertow","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R11-10-20210205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1740774511399128","article-title":"The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.","volume":"8","author":"Pritchett","year":"2011","journal-title":"Clin Trials"},{"key":"R12-10-20210205","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"R13-10-20210205","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis.","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N Engl J Med"},{"key":"R14-10-20210205","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"R15-10-20210205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.","volume":"51","author":"St Peter","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R16-10-20210205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R17-10-20210205","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","article-title":"Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.","volume":"164","author":"Tamez","year":"2012","journal-title":"Am Heart J"},{"key":"R18-10-20210205","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cardfail.2011.08.006","article-title":"Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.","volume":"17","author":"Choi","year":"2011","journal-title":"J Card Fail"},{"key":"R19-10-20210205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cvr\/cvr133","article-title":"Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats.","volume":"91","author":"Bae","year":"2011","journal-title":"Cardiovasc Res"},{"key":"R20-10-20210205","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2353\/ajpath.2010.091292","article-title":"Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.","volume":"177","author":"Kong","year":"2010","journal-title":"Am J Pathol"},{"key":"R21-10-20210205","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.numecd.2009.07.009","article-title":"Vitamin D deficiency in the spontaneously hypertensive heart failure SHHF prone rat.","volume":"20","author":"Przybylski","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R22-10-20210205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jsbmb.2012.06.004","article-title":"The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.","volume":"132","author":"Meems","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R23-10-20210205","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.111.032680","article-title":"Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy.","volume":"124","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"R24-10-20210205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ndt\/gfn549","article-title":"Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats.","volume":"24","author":"Koleganova","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R25-10-20210205","doi-asserted-by":"crossref","first-page":"G1036","DOI":"10.1152\/ajpgi.00243.2005","article-title":"1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport.","volume":"289","author":"Kolek","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R26-10-20210205","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R27-10-20210205","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R28-10-20210205","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","article-title":"Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.","volume":"82","author":"Lau","year":"2012","journal-title":"Kidney Int"},{"key":"R29-10-20210205","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"R30-10-20210205","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/CIRCULATIONAHA.112.104828","article-title":"Klotho: a master regulator of cardiovascular disease C","volume":"125","author":"Moe","year":"2012","journal-title":"irculation"}],"container-title":["Current Opinion in Nephrology & Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNH.0b013e328365b3a3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:30:09Z","timestamp":1620963009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041552-201311000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnh.0b013e328365b3a3","relation":{},"ISSN":["1062-4821"],"issn-type":[{"value":"1062-4821","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}